Media Articles Related to Exforge HCT (Amlodipine / Hydrochlorothiazide / Valsartan)
Vitamin D 'ineffective as treatment for hypertension'
Source: Cardiovascular / Cardiology News From Medical News Today [2015.03.19]
Researchers report that vitamin D supplementation does not work as an antihypertensive agent and cannot be recommended to control high blood pressure.
Cherokee Nation Keeps Hypertension in Check
Source: MedPage Today Cardiovascular [2015.03.19]
(MedPage Today) -- Million Hearts Champion Brett Gray says showing patients you care is key to compliance.
ACC: Folate Supplements Cut Strokes in Hypertension
Source: MedPage Today Cardiovascular [2015.03.19]
(MedPage Today) -- Hypertensive patients with low blood folate levels gain big benefit.
Lowering Ocular Hypertension Meds Needn't Boost Glaucoma Risk
Source: Medscape Ophthalmology Headlines [2015.03.18]
Patients with ocular hypertension (OH) can often lower their medication dosage and cut costs without a significantly increased glaucoma risk, Chinese researchers say.
Reuters Health Information
Expanding blood pressure screenings beyond primary care can improve hypertension detection
Source: Hypertension News From Medical News Today [2015.03.16]
Expanding blood pressure screenings to non-primary care settings can help identify more patients with high blood pressure, commonly called hypertension, and could contribute to better hypertension...
Published Studies Related to Exforge HCT (Amlodipine / Hydrochlorothiazide / Valsartan)
24-Hour ambulatory blood pressure response to combination valsartan/hydrochlorothiazide and amlodipine/hydrochlorothiazide in stage 2 hypertension by ethnicity: the EVALUATE study. [2010.11]
Several studies reported racial/ethnic differences in blood pressure (BP) response to antihypertensive monotherapy. In a 10-week study of stage 2 hypertension, 320/25 mg valsartan/hydrochlorothiazide (HCTZ) reduced ambulatory BP (ABP) significantly more effectively than 10/25 mg amlodipine/HCTZ...
Effects of force-titrated valsartan/hydrochlorothiazide versus amlodipine/hydrochlorothiazide on ambulatory blood pressure in patients with stage 2 hypertension: the EVALUATE study. [2009.06]
BACKGROUND: Previous studies using the combination of angiotensin-receptor blockers and hydrochlorothiazide (HCTZ) have shown superior ambulatory blood pressure (ABP) reduction in study participants with stage 2 hypertension compared with monotherapy. OBJECTIVE: This multicenter, double-blind, parallel group, forced-titration study of individuals with stage 2 hypertension, compared the efficacy of valsartan and amlodipine in combination with HCTZ on ABP reduction... CONCLUSION: On the basis of ABP monitoring but not office measurements, the fixed-dose combination of valsartan/HCTZ is a significantly more effective treatment regimen than amlodipine/HCTZ, with similar tolerability.
Clevidipine: a review of its use in the management of acute hypertension. 
ABSTRACT: Clevidipine (Cleviprex), a late-generation dihydropyridine calcium channel antagonist available as a lipid emulsion for intravenous infusion, is approved in the US for the reduction of blood pressure (BP) when oral therapy is not feasible or desirable... Most adverse events associated with clevidipine were mild or moderate in severity and considered unrelated to study drug, with the most commonly reported being headache, nausea, chest discomfort, and vomiting.
Effects of valsartan or ramipril addition to amlodipine/hydrochlorothiazide
combination on left ventricular mass in diabetic hypertensive patients with left
ventricular hypertrophy. 
CONCLUSIONS: Valsartan addition to dual therapy with amlodipine + HCTZ was more
24-Hour ambulatory blood pressure control with triple-therapy amlodipine, valsartan and hydrochlorothiazide in patients with moderate to severe hypertension. [2011.10]
To determine the effectiveness and safety of once-daily combination therapy with amlodipine, valsartan and hydrochlorothiazide for reducing ambulatory blood pressure (ABP) in patients with moderate to severe hypertension, a multicenter, double-blind study was performed (N=2271) that included ABP monitoring in a 283-patient subset.
Clinical Trials Related to Exforge HCT (Amlodipine / Hydrochlorothiazide / Valsartan)
Effectiveness of EXforge® and Nifedipine treAtment coMparison in Treating Chinese Hypertensive Patients [Recruiting]
This study is to demonstrate that valsartan/amlodipine 80/5 mg has superior efficacy
compared with nifedipine 30mg alone in reducing the mean sitting diastolic blood pressure
(MSDBP) and mean sitting systolic blood pressure (MSSBP) from baseline in patients with mild
to moderate hypertension not adequately controlled with monotherapy.
A Phase I Clinical Trial to Investigate the Pharmacokinetic Interactions and Safety Between Exforge Tab. and Crestor Tab. in Healthy Male Subjects [Not yet recruiting]
EXforge As Compared to Losartan Treatment in Stage 2 Systolic Hypertension [Recruiting]
This study will compare the antihypertensive efficacy and safety of a
valsartan/amlodipine-based treatment with a losartan-based treatment in patients with Stage
2 systolic hypertension (high blood pressure, mean systolic blood pressure greater than 160
and less than 200 mmHg.
Clinical Trial to Assess the Pharmacokinetic Characteristics of Lodivixx Tab. 5/160mg in Healthy Male Subjects (N=60) [Recruiting]
The purpose of this study is to assess the pharmacokinetic characteristics of valsartan and
S-amlodipine after single oral administration of Exforge tab. 10/160mg, a combination
formulation of valsartan and amlodipine as reference drug and Lodivixx tab. 5/160mg, a
combination formulation of valsartan and S-amlodipine as test drug in healthy male adults.
Additionally the safety and tolerability of two drugs will be evaluated.
Clinical Trial to Assess the Pharmacokinetic Characteristics of Lodivixx Tab. 5/160mg in Healthy Male Subjects [Recruiting]
Reports of Suspected Exforge HCT (Amlodipine / Hydrochlorothiazide / Valsartan) Side Effects
Oedema Peripheral (19),
Blood Pressure Increased (18),
Blood Pressure Decreased (15),
Blood Pressure Fluctuation (13),
Back Pain (12),
Pain (11), more >>